

Appendix 3Y

Change of Director's Interest Notice

Name of entity	Incannex Healthcare Limited
ABN	93 096 635 246

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Sudhanshu AGARWAL
Date of last notice	19 October 2020

Part 1 - Change of director's relevant interests in securities

Direct or indirect interest	Direct and Indirect
Nature of indirect interest	Dr Agarwal is a shareholder, CEO and director of Cannvalate Pty Ltd ("Cannvalate"). 'Indirect' positions disclosed in this Appendix 3Y are held by Cannvalate - Dr Agarwal does not have sole discretion over the acquisition or disposal of these positions.
Date of change	3 December 2020
No. and class of securities held prior to change	Direct 5,600,000 fully paid ordinary shares ("IHL") 30,703,593 unlisted performance rights 200,000,000 \$0.20 unlisted options expiry 30-Sep-21 Indirect 32,000,000 fully paid ordinary shares ("IHL") 14,000,000 \$0.06 unlisted options expiry 01-Dec-20 16,000,000 \$0.08 unlisted options expiry 01-Dec-20 18,000,000 \$0.10 unlisted options expiry 01-Dec-20 20,000,000 \$0.12 unlisted options expiry 01-Dec-20 20,000,000 \$0.14 unlisted options expiry 01-Dec-20
Number and class of securities acquired	7,263,280 fully paid ordinary shares ("IHL") (Direct)
Number and class of securities disposed	7,263,280 unlisted performance rights (Direct) 88,000,000 unlisted options (Indirect/expired)
Value/Consideration	Nil for all changes
No. of securities held after change	Direct 12,863,280 fully paid ordinary shares ("IHL") 23,440,313 unlisted performance rights 200,000,000 \$0.20 unlisted options expiry 30-Sep-21 Indirect 32,000,000 fully paid ordinary shares ("IHL")
Nature of change	Conversion of performance rights upon achievement of performance hurdle and expiry of unlisted options

Part 2 – Change of director's interests in contracts – no change

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/a
If prior written clearance was provided, on what date was this provided?	N/a